Healthcare [ 12/13 ] | Biotechnology [ 92/159 ]
NYSE | Common Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 23 | -1.63 Decreased by -75.27% | -1.09 Decreased by -49.54% |
Aug 14, 23 | -1.07 Increased by 0% | -1.14 Increased by +6.14% |
Apr 3, 23 | -0.38 Increased by +47.22% | -1.05 Increased by +63.81% |
Mar 1, 23 | -1.05 Decreased by -40% | -1.05 |
Nov 8, 22 | -0.93 Decreased by -165.71% | -1.01 Increased by +7.92% |
Aug 8, 22 | -1.07 Decreased by -214.71% | -0.64 Decreased by -67.19% |
May 4, 22 | -0.72 Decreased by -56.52% | -0.58 Decreased by -24.14% |
Mar 2, 22 | -0.75 Decreased by -200% | -0.25 Decreased by -200% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 23 | 0 Decreased by N/A% | -14.72 M Decreased by -95.81% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0 Decreased by N/A% | -9.54 M Decreased by -10.31% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0 Decreased by N/A% | -29.44 M Decreased by -402.9% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0 Decreased by N/A% | -3.02 M Increased by +48.93% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0 Decreased by N/A% | -7.52 M Decreased by -163.87% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0 Decreased by N/A% | -8.65 M Decreased by -242.47% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 0 Decreased by N/A% | -5.85 M Decreased by -82.98% | Decreased by N/A% Decreased by N/A% |
Dec 31, 21 | 0 Decreased by N/A% | -5.91 M Decreased by -246.98% | Decreased by N/A% Decreased by N/A% |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.